No annual revenue total was found in Dyne Therapeutics, Inc.'s SEC filings.
Dyne Therapeutics, Inc. (DYN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$405.1 million. As of Sep 30, 2026 it held $1.1 billion in cash and investments and $218.9 million in total debt.
Revenue
—
Net income (TTM)
$-604.92M
-42.7% vs year-ago TTM
Operating cash flow (TTM)
$-564.53M
-50.3% vs year-ago TTM
Free cash flow (TTM)
$-568.76M
-50.4% vs year-ago TTM
EPS
$-3.47
-3.0% vs prior year
Dividend per share
None
Shares outstanding
164.95M
+61.2% vs prior year
Net cash
$915.51M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DYN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1818794
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$468.2M | -$343.9M | -$242.2M | -$171.0M | -$150.0M |
| Net income | -$446.2M | -$317.4M | -$235.9M | -$168.1M | -$149.3M |
| Diluted EPS | -$3.47 | -$3.37 | -$3.95 | -$3.23 | — |
| Operating cash flow | -$403.2M | -$292.4M | -$188.2M | -$153.6M | -$119.6M |
| Free cash flow | -$405.1M | -$294.7M | -$188.9M | -$156.7M | -$123.2M |
| Total assets | $1.2B | $691.2M | $165.1M | $306.3M | $425.7M |
| Total liabilities | $214.8M | $61.4M | $73.8M | $54.0M | $57.5M |
| Stockholders' equity | $972.1M | $629.8M | $91.3M | $252.4M | $368.2M |
| Cash and investments | $1.1B | $642.3M | $123.1M | $256.0M | $376.6M |
| Total debt | $169.2M | $24.0M | $27.4M | $30.5M | $32.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 22, 2026 | Jul 21, 2026 |
All 796 Dyne Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.